This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Top Dow Stocks to Buy on the Dip for a Stronger Portfolio
by Nalak Das
A fundamentally stable U.S. economy, which is growing for history setting 11 years, albeit at a slow pace and a dovish Fed in 2019 are the two major drivers of the Dow.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.63, moving -0.87% from the previous trading session.
Clovis Gains Rights to Pre-Clinical Cancer Program for $12M
by Zacks Equity Research
Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
by Zacks Equity Research
Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
Merck's Two HIV Drugs Get FDA Approval for Expanded Use
by Zacks Equity Research
Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.
Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label
by Zacks Equity Research
CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.
Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
Company News for Sep 23, 2019
by Zacks Equity Research
Companies In The News Are: MDR, MRK, NFLX, XLNX
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
by Kinjel Shah
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
by Zacks Equity Research
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $82.51, marking a +0.59% move from the previous day.
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
by Zacks Equity Research
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
by Zacks Equity Research
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
by Kinjel Shah
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
by Zacks Equity Research
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Renal Cell Carcinoma Space in Focus: Some Key Developments
by Ekta Bagri
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Momentum ETFs & Stocks in Focus as Trump Delays Tariff Hike
by Sweta Killa
While the broader stock market is expected to move higher, momentum investing will likely take charge as investors seek higher returns in a short span.
Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
by Zacks Equity Research
Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $82.92, moving +1.51% from the previous trading session.
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
4 Big Drugmakers Boasting Impressive Oncology Pipelines
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Merck Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merck & Co. has been struggling lately, but the selling pressure may be coming to an end soon.